Intratympanic Dexamethasone Role in Hearing Protection in Cancer Patients

Introduction The study aims to determine the role of intratympanic dexamethasone (ITD) on hearing profile patients with head and neck cancer post-chemoradiotherapy. Study design This employs a prospective case-control design. Subjects methods In total 834 were evaluated for eligibility. Seven hundred eleven excluded because they didn’t meet inclusion criteria. A cases out 123 diagnosed which treatment protocol included cisplatin concurrent radiotherapy recruited. Before each session, ITD was injected into one ear (experimental ear) while other same patient served as control. Pure-tone audiometry (PTA) distortion product otoacoustic emissions (DPOAE) test results baseline follow-up examinations in sixth 12th weeks compared within between control ears. Results For pure tone thresholds, significant threshold change noticed at 8 kHz experimental group six ≥ 6 group. At 12 weeks, high frequencies significantly affected 4 When across groups week, emissions, showed loss more side (Wilcoxon signed-rank test). Conclusion functions less effectively higher basal turn cochlea is susceptible ototoxicity. might have potential reduction cisplatin-induced loss.